Work

Erratum: Effect of GLP ‐1 receptor agonist treatment on body weight in obese antipsychotic‐treated patients with schizophrenia: A randomized, placebo‐controlled trial

Year: 2018

Type: erratum

Abstract: "Treatment of antipsychotic-associated obesity with a GLP-1 receptor agonist (GLP-1RA): The TAO trial" is the first clinical investigation of GLP-1RA treatment (exenatide 2 mg once-weekly or placebo) in antipsychotic-treated schizophrenia patients with obesity.1 Recently, we published the main results from the TAO trial as an original article in Diabetes, Obesity and Metabolism.2 We regret to report, that further analyses of the TAO dataset have revealed an error in our secondary analyses presented in the original publication.

Source: Diabetes Obesity and Metabolism

DOI: 10.1111/dom.13204